Security key
53630L100
LIPELLA PHARMACEUTICALS INC. - Common Stock (LIPO)
CUSIP: 53630L100
Q3 2023 13F Holders as of 30 Sep 2023
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 39,640
- Total 13F value
- $59,463
- Share change
- +1,084
- SEC-reported price per share
- $1.50
- Number of holders
- 4
- Value change
- +$1,626
- Number of buys
- 2
- Number of sells
- 1
- Shares outstanding
- 1,231,122
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2023
Institutions
4
Top holders
4
LIPO full security history
Ownership snapshot
Full 13F holder table
LIPELLA PHARMACEUTICALS INC. SEC filings
LIPELLA PHARMACEUTICALS INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of LIPO - LIPELLA PHARMACEUTICALS INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD GROUP INC
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
4/5
Latest evidence
30 Jun 2023
13F
3/4/5
Lead comparable stake: 2.8%
1 rows are not safely comparable across share classes.
Quick read
VANGUARD GROUP INC leads the comparable SEC ownership view at 2.8%.
4 of 5 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD GROUP INC's linked filing trail.
Comparable ownership
Top 4
VANGUARD GROUP INC
2.8%
UBS Group AG
0.2%
Tower Research Capital LLC (TRC)
0.13%
WELLS FARGO & COMPANY/MN
0%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-5 of 5 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
Company
|
2.8%
|
$73,873
34,520 shares
|
— | 30 Jun 2023 |
| UBS Group AG |
13F
Company
|
0.2%
|
$5,181
2,421 shares
|
— | 30 Jun 2023 |
| Tower Research Capital LLC (TRC) |
13F
Company
|
0.13%
|
$3,437
1,606 shares
|
— | 30 Jun 2023 |
| WELLS FARGO & COMPANY/MN |
13F
Company
|
0%
|
$19
9 shares
|
— | 30 Jun 2023 |
| David S. Battleman |
3/4/5
Director
|
—
class O/S missing
|
—
25,000 shares
|
— | 16 Jun 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
4
Shares
39,640
Rows available
4
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2023 vs Q2 2023 Across Filers
Q2 2023 holders
4
Q3 2023 holders
4
Holder diff
0
| Investor | Q2 2023 Shares | Q3 2023 Shares | Share Diff | Share Chg % | Q2 2023 value | Q3 2023 value | Value change | Value Chg % |
|---|